We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals Inc.’s new non-opioid ... The medication, called Journavx, got US regulatory clearance in January. The financial success of new drugs largely depends on how they’re ...